Blog

Kimryn Rathmell: New drug type in the kidney cancer space and the value of rare disease research

Photo from Kimryn Rathmell/X

Mar 8, 2024, 19:07

Kimryn Rathmell: New drug type in the kidney cancer space and the value of rare disease research

Kimryn Rathmell, Director of

“I’m excited to see that the discovery of a drug to target HIF-2alpha, first developed for a rare disease (VHL syndrome), is now making a difference in common kidney cancers. This adds a new drug type in the kidney cancer space and highlights the value of rare disease research.”

Source: Kimryn Rathmell/X

cancer HIF-2alpha kidney cancer Kimryn Rathmell National Cancer Institute NCI OncoDaily Oncology rare disease research VHL syndrome Von Hippel-Lindau disease

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage